title: (153)Sm-EDTMP appears to accumulate only trivially within peritoneal ascites.
abstract: (153)Sm-lexidronam (EDTMP) is a therapeutic radiopharmaceutical used for palliation of pain resulting from osseous metastatic disease.
  
  
  METHODS
  We recently treated with (153)Sm-EDTMP a patient who had extensive osseous metastases and malignant ascites requiring intermittent drainage from an indwelling catheter. Because we could find no useful data regarding quantification of accumulation of this agent within ascites, we opted to assay the fluid after treatment.
  
  
  RESULTS
  The measured ratio of (153)Sm-EDTMP activity in peritoneal fluid (1.71 L) relative to injected dose was 0.01% (i.e., trivially above background level).
  
  
  CONCLUSIONS
  To our knowledge, this represents the first published measurement of (153)Sm-EDTMP accumulation within peritoneal fluid. This information may be useful to the nuclear medicine community since malignant ascites is not uncommon in patients with widely metastatic carcinoma and such patients may be referred for (153)Sm-EDTMP therapy.
authors.affiliation: Department of Nuclear Medicine, Kaiser Permanente Medical Center, Santa Clara, California, USA.
authors.forename: Gene A
authors.initials: GA
authors.lastname: Schreck
authors.forename: Ryan D
authors.initials: RD
authors.lastname: Niederkohr
mesh_terms: D001201:Ascites / Q000150:complications / Q000378:metabolism*; D001202:Ascitic Fluid / Q000378:metabolism*; D001943:Breast Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000378:metabolism* / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000378:metabolism* / Q000627:therapeutic use; D010534:Peritoneal Neoplasms / Q000150:complications / Q000556:secondary
chemical_list: D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C061972:samarium Sm-153 lexidronam